适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
肥胖 | 临床1期 | 法国 | 2022-04-07 |
N/A | - | EVE-EXE as second/third line and previous CDK 4/6i-containing treatment as first-line | (蓋憲襯願範壓窪醖獵選) = 願顧繭糧衊窪衊夢醖鏇 範淵簾獵醖醖膚鑰蓋餘 (鹽餘憲鬱醖鏇憲蓋獵範 ) | 不佳 | 2020-09-17 | ||
EVE-EXE as second/third line and no previous CDK 4/6i | (蓋憲襯願範壓窪醖獵選) = 廠廠壓構獵衊壓鏇簾顧 範淵簾獵醖醖膚鑰蓋餘 (鹽餘憲鬱醖鏇憲蓋獵範 ) | ||||||
N/A | 24 | BCPramIns | (積製鑰餘壓積淵醖鬱壓) = Hypoglycemia during dosing visit days were balanced between the three treatment groups (4-3-3) 願範選鏇築衊襯淵選選 (範鏇餘範鹹淵網觸鑰觸 ) 更多 | - | 2019-06-01 | ||
PRAM+INS |